Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 558

Similar articles for PubMed (Select 18722269)

1.

Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation.

Dahle J, Bruland OS, Larsen RH.

Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):186-92. doi: 10.1016/j.ijrobp.2008.05.029.

PMID:
18722269
2.

High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.

Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W.

Cancer Res. 1999 Jun 1;59(11):2635-43.

3.

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

Wiseman GA, White CA, Sparks RB, Erwin WD, Podoloff DA, Lamonica D, Bartlett NL, Parker JA, Dunn WL, Spies SM, Belanger R, Witzig TE, Leigh BR.

Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):181-94.

PMID:
11418315
4.

In vitro cytotoxicity of low-dose-rate radioimmunotherapy by the alpha-emitting radioimmunoconjugate Thorium-227-DOTA-rituximab.

Dahle J, Krogh C, Melhus KB, Borrebaek J, Larsen RH, Kvinnsland Y.

Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):886-95. doi: 10.1016/j.ijrobp.2009.04.062. Epub 2009 Aug 11.

PMID:
19679402
5.

Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.

Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, Raubitschek A, Karvelis K, Schultheiss T, Witzig TE, Belanger R, Spies S, Silverman DH, Berlfein JR, Ding E, Grillo-López AJ.

Eur J Nucl Med. 2000 Jul;27(7):766-77.

PMID:
10952488
6.
7.

Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate.

Dahle J, Borrebaek J, Jonasdottir TJ, Hjelmerud AK, Melhus KB, Bruland ØS, Press OW, Larsen RH.

Blood. 2007 Sep 15;110(6):2049-56. Epub 2007 May 29.

8.

211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.

Bäck T, Andersson H, Divgi CR, Hultborn R, Jensen H, Lindegren S, Palm S, Jacobsson L.

J Nucl Med. 2005 Dec;46(12):2061-7.

9.

Comparing high LET 227Th- and low LET 177Lu-trastuzumab in mice with HER-2 positive SKBR-3 xenografts.

Abbas N, Heyerdahl H, Bruland ØS, Brevik EM, Dahle J.

Curr Radiopharm. 2013 Jun 6;6(2):78-86.

PMID:
23551110
10.

Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate (227)Th-rituximab.

Dahle J, Jonasdottir TJ, Heyerdahl H, Nesland JM, Borrebaek J, Hjelmerud AK, Larsen RH.

Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):93-102. doi: 10.1007/s00259-009-1197-7. Epub .

PMID:
19593562
11.

Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.

Behr TM, Sgouros G, Stabin MG, Béhé M, Angerstein C, Blumenthal RD, Apostolidis C, Molinet R, Sharkey RM, Koch L, Goldenberg DM, Becker W.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3031s-3043s.

PMID:
10541340
12.

Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin).

Hernandez MC, Knox SJ.

Semin Oncol. 2003 Dec;30(6 Suppl 17):6-10. Review.

PMID:
14710397
13.

Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.

Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, Romaguera J, Cabanillas F, Neelapu SS, Banay R, Fayad L, Wayne Saville M, Kwak LW.

Ann Oncol. 2009 Apr;20(4):709-14. doi: 10.1093/annonc/mdn692. Epub 2009 Jan 15.

14.

90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.

Griffiths GL, Govindan SV, Sharkey RM, Fisher DR, Goldenberg DM.

J Nucl Med. 2003 Jan;44(1):77-84.

15.

Initial evaluation of (227)Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy.

Dahle J, Borrebaek J, Melhus KB, Bruland OS, Salberg G, Olsen DR, Larsen RH.

Nucl Med Biol. 2006 Feb;33(2):271-9.

PMID:
16546683
16.

Radioimmunotherapy for B-cell non-Hodgkin lymphoma.

Witzig TE.

Best Pract Res Clin Haematol. 2006;19(4):655-68. Review.

PMID:
16997175
17.

High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment.

Cremonesi M, Ferrari M, Grana CM, Vanazzi A, Stabin M, Bartolomei M, Papi S, Prisco G, Ferrucci PF, Martinelli G, Paganelli G.

J Nucl Med. 2007 Nov;48(11):1871-9. Erratum in: J Nucl Med. 2007 Dec;48(12):2027.

18.

Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma.

Wiseman GA, Leigh B, Erwin WD, Lamonica D, Kornmehl E, Spies SM, Silverman DH, Witzig TE, Sparks RB, White CA.

Cancer. 2002 Feb 15;94(4 Suppl):1349-57.

19.
20.

Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross-organ beta doses.

Ugur O, Kostakoglu L, Hui ET, Fisher DR, Garmestani K, Gansow OA, Cheung NK, Larson SM.

Nucl Med Biol. 1996 Jan;23(1):1-8.

PMID:
9004907
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk